Bristol-Myers Squibb (Strategic Investments)
About
Bristol-Myers Squibb (Strategic Investments) BMS makes strategic investments directly from its balance sheet rather than through a dedicated CVC fund. Typical deal sizes run $10-50M, with fewer than 2 new investments per year. The approach is selective and strategically driven. The major venture investment was $180M in Owkin, a French AI company developing technology for clinical trial design, in 2022. BMS also anchored Life Science Partners' record €600M European VC fund. On the M&A side, the s
Industries
Stage focus
Series ASeries B+
Geography
USEurope
Notable investments
- Owkin
- Mirati Therapeutics
- Karuna Therapeutics
Raising from Bristol-Myers Squibb (Strategic Investments)?
I've worked with founders across the industrial stack. If Bristol-Myers Squibb (Strategic Investments) is on your list, I can help you map the introduction path, sharpen the narrative, and run a tight process.
Talk to Dan